Literature DB >> 24018404

Seroprevalence of hepatitis B and immune response to hepatitis B vaccination in Chinese college students mainly from the rural areas of western China and born before HBV vaccination integrated into expanded program of immunization.

Xue-Yan Liao1, Zhen-Zuo Zhou2, Fu-Bang Wei2, Han-Ning Qin2, Yuan Ling2, Rong-Cheng Li3, Yan-Ping Li3, Yi Nong3, Kui-Xia Sun1, Jie Li1, Hui Zhuang1.   

Abstract

The prevalence of hepatitis B surface antigen (HBsAg) in a population aged 15 y or older was high in China, but an immunization strategy for this population was unavailable. We investigated the seroprevalence of hepatitis B and immune response to HBV vaccine in Chinese college students (n=2040 participants), 11.1%, 80.8%, and 8.1% had confirmed, unknown and no HBV vaccination history, respectively. The seropositive rates for HBsAg, anti-HBs sole and anti-HBs plus anti-HBc were 12.6%, 25.7%, and 30.1%, respectively. The HBsAg seropositive rate was significantly lower in participants with confirmed HBV vaccination history than in those with unknown or no vaccination history (5.3%, 13.6%, and 12.6%, respectively, P=0.0019). The anti-HBs alone seropositive rate was significantly higher in participants with confirmed HBV vaccination history than in those with unknown or no vaccination history (37.6%, 25.3%, and 13.8%, respectively, P<0.0001). Participants negative for HBsAg, anti-HBs, and anti-HBc at baseline (n=600) were given three doses of recombinant HBV vaccine (GlaxoSmithKline) at month 0, 1, and 6. Robust immune response was elicited after two and three doses (seroprotective rate: 91.9% and 99.0%, respectively, and geometric mean concentration [GMC]: 95.8 and 742.6 IU/L, respectively). Fourteen months after the third dose, the anti-HBs seroprotective rate of the group remained more than 97%. The seroprotective rates and GMCs did not differ significantly by vaccination history. This study suggested that three doses of 20 μg HBV vaccine were needed for college students negative for HBsAg, anti-HBs, and anti-HBc to ensure high seroprotective rates and concentrations.

Entities:  

Keywords:  college students; hepatitis B; hepatitis B vaccine; immune response; seroprevalence

Mesh:

Substances:

Year:  2013        PMID: 24018404      PMCID: PMC4181036          DOI: 10.4161/hv.26311

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  30 in total

1.  Hepatitis B booster vaccination for healthcare workers.

Authors:  T Yoshida; I Saito
Journal:  Lancet       Date:  2000-04-22       Impact factor: 79.321

2.  [Technical guide for adult hepatitis B immunization in China].

Authors:  Fu-Qiang Cui
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2011-12

Review 3.  Hepatitis B vaccine boosters: is there a clinical need in high endemicity populations?

Authors:  T Jacob John; Graham Cooksley
Journal:  J Gastroenterol Hepatol       Date:  2005-01       Impact factor: 4.029

4.  Hepatitis B vaccines.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2009-10-01

5.  From Abbott ARCHITECT anti-HBc to Anti-HBc II--improved performance in detecting antibodies to hepatitis B core antigen.

Authors:  Tapio Seiskari; Helena Lehtisaari; Anna-Maija Haapala; Janne Aittoniemi
Journal:  J Clin Virol       Date:  2009-12-03       Impact factor: 3.168

Review 6.  Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched.

Authors:  Yin-Chu Chien; Chyi-Feng Jan; Hsu-Sung Kuo; Chien-Jen Chen
Journal:  Epidemiol Rev       Date:  2006-06-16       Impact factor: 6.222

7.  Hepatitis B: vaccination programmes in Europe--an update.

Authors:  P Van Damme
Journal:  Vaccine       Date:  2001-03-21       Impact factor: 3.641

8.  [A study of immune response to hepatitis B vaccine & HBV DNA in isolated anti-HBc positive subjects].

Authors:  Hee Jeong Koh; Soon Duck Kim; Ji Ho Choi; Sung Ryul Kim; Jin Soo Lee
Journal:  J Prev Med Public Health       Date:  2005-05

9.  Hepatitis B immunity in adolescents and necessity for boost vaccination: 23 years after nationwide hepatitis B virus vaccination program in Taiwan.

Authors:  John Jenn-Yenn Lu; Chi-Chia Cheng; Shieu-Ming Chou; Chang-Bor Hor; Yi-Chen Yang; Hsiang-Ling Wang
Journal:  Vaccine       Date:  2009-08-19       Impact factor: 3.641

10.  Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination.

Authors:  Xiaofeng Liang; Shengli Bi; Weizhong Yang; Longde Wang; Gang Cui; Fuqiang Cui; Yong Zhang; Jianhua Liu; Xiaohong Gong; Yuansheng Chen; Fuzhen Wang; Hui Zheng; Feng Wang; Jing Guo; Zhiyuan Jia; Jingchen Ma; Huaqing Wang; Huiming Luo; Li Li; Shuigao Jin; Stephen C Hadler; Yu Wang
Journal:  Vaccine       Date:  2009-09-01       Impact factor: 3.641

View more
  9 in total

1.  A new vaccine escape mutant of hepatitis B virus causes occult infection.

Authors:  Qing Ye; Shi-Qiang Shang; Wei Li
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Strategy vaccination against Hepatitis B in China.

Authors:  Xueyan Liao; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Hepatitis B virus infections among health professional students in Mwanza city,Tanzania in 2016.

Authors:  Mariam M Mirambo; Emmanuel Mkumbo; Hadija Selega; Betrand Msemwa; Martha F Mushi; Vitus Silago; Jeremiah Seni; Stephen E Mshana; Christa Kasang
Journal:  Arch Public Health       Date:  2020-08-18

4.  A cross-sectional sero-survey on preoperative HBV vaccination policy in Poland.

Authors:  Maria Ganczak; Marcin Korzen; Alina Jurewicz; Zbigniew Szych
Journal:  BMC Infect Dis       Date:  2017-07-25       Impact factor: 3.090

5.  Seroprevalence of anti-HBc, risk factors of occupationally acquired HBV infection and HBV vaccination among hospital staff in Poland: a multicenter study.

Authors:  Maria Ganczak; Katarzyna Topczewska; Maria Budnik-Szymoniuk; Marcin Korzeń
Journal:  BMC Public Health       Date:  2019-03-12       Impact factor: 4.135

6.  Risk factors of hepatitis B virus infection between vaccinated and unvaccinated groups among spouses in 2006 and 2014: a cross-sectional study in Beijing.

Authors:  Yiwei Guo; Pei Gao; Huai Wang; Jiang Wu; Qian Bai; Lieyu Huang; Shuo Li; Min Lv; Xuefeng Shi
Journal:  Hum Vaccin Immunother       Date:  2019-08-01       Impact factor: 3.452

7.  Prevalence of hepatitis B virus, hepatitis C virus, human immunodeficiency virus and Treponema pallidum infections in hospitalized patients before transfusion in Xiangya hospital Central South University, China from 2011 to 2016.

Authors:  Wei-Wei Cao; Rong-Rong Zhou; Xinghua Ou; Ling-Xi Shi; Chao-Qi Xiao; Ting-Yin Chen; Hua Tan; Xue-Gong Fan; Bi-Juan Li; Ning Li
Journal:  BMC Infect Dis       Date:  2018-04-02       Impact factor: 3.090

Review 8.  Long-term impact of infant immunization on hepatitis B prevalence: a systematic review and meta-analysis.

Authors:  Kate Whitford; Bette Liu; Joanne Micallef; J Kevin Yin; Kristine Macartney; Pierre Van Damme; John M Kaldor
Journal:  Bull World Health Organ       Date:  2018-05-14       Impact factor: 9.408

9.  Cost-utility analysis of newborn hepatitis B immunization in Beijing.

Authors:  Yiwei Guo; Yong Yang; Qian Bai; Zhengwei Huang; Zongwu Wang; Dongxia Cai; Shuo Li; Xiaowei Man; Xuefeng Shi
Journal:  Hum Vaccin Immunother       Date:  2020-10-05       Impact factor: 3.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.